From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India

NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together leading experts to discuss how Next-Generation Sequencing (NGS), machine learning, and advanced molecular diagnostics are reshaping prenatal care in India and beyond. 

🔬 A New Era: AI + NGS in Prenatal Screening 

“Prenatal screening is evolving from basic aneuploidy detection to an integrated, AI-powered, all-in-one genetic screening ecosystem, enabling earlier detection and better maternal–fetal outcomes.” Dr. Tang Hung Sang, Medical Director, Medical Genetics Institute. 

Dr. Tang emphasized that the future lies in unified prenatal platforms capable of delivering comprehensive insights—aneuploidies, carrier status, and single gene disorders within a single workflow supported by advanced computational algorithms. 

The India Imperative: Tackling Recessive Diseases Early 

A powerful call to action came from Dr. Seema Thakur, Senior Consultant in Genetic and Fetal Medicine, who highlighted India’s urgent need for expanded carrier screening to address the country’s significant burden of recessive disorders: 

• 1 in 44 births may be affected by a major congenital anomaly, including major genetic burden of Down syndrome, sickle cell disease, beta thalassemia, G6PD deficiency, metabolic disorders. 

• 42,000 babies with SCD are born in India each year. SCD contributes to significant morbidity and mortality, especially without early diagnosis and care. Many children with SCD face severe health complications and historically high early childhood mortality. 

• Most parents are asymptomatic carriers and unaware of their risks. India’s National Sickle Cell Anaemia Elimination Mission (launched in 2023) aims to eliminate sickle cell disease as a public health problem by 2047 through large-scale screening of ~70 million people aged 0–40 years in high-prevalence districts, alongside genetic counseling and comprehensive care. 

Her message was clear: widespread carrier screening before or early during pregnancy together with prenatal diagnosis is the only sustainable path to reducing the incidence of recessive genetic diseases in India. 

🧬 Introducing triSure NIPT: Beyond Traditional Aneuploidy Testing 

During the session, Gene Solutions showcased triSure NIPT, which redefines what clinicians can expect from a prenatal test. triSure NIPT sets a new standard in comprehensive maternal–fetal health by integrating four critical screening scopes into a single blood draw: 

1. Aneuploidies & Microdeletions (Fetal): All 27 chromosomal aneuploidies plus the five most common clinically significant copy number variants (CNVs). 
2. Dominant Monogenic Disorders: Screening for 25 dominant single gene disorders associated with serious fetal developmental conditions—providing clinicians with actionable, early insights to guide counseling and intervention. 
3. Integrated Carrier Screening (Recessive Diseases): Carrier status detection for 18 clinically relevant recessive disorders, including alpha and beta thalassemia, enabling parents and clinicians to identify hidden carrier risks during pregnancy. 
4. Gestational Diabetes Risk Prediction: Assessing gestational diabetes mellitus (GDM) risk in the first trimester.  

triSure NIPT delivers accuracy and reliability by combining size-based and count-based algorithms to distinguish maternal from fetal DNA. A machine learning model further enhances performance even when the fetal fraction is below 4%, helping reduce reruns and resampling. Clinical performance is supported by 15 peer-reviewed publications and real-world evidence from over 2 million comprehensive NIPT tests. 

💛 Empowering More Confident Pregnancies 

With India’s growing emphasis on early, proactive maternal–fetal care, triSure NIPT offers a next-generation solution that aligns with clinical needs and regional public health. 

Learn more:
https://vcard.okr.business/genesolutions.com-our-test-trisure-procare
https://vcard.okr.business/genesolutions.com-our-test-trisure-nipt 

Important: NIPT is a screening test and does not provide a definitive diagnosis. High-risk results should be followed by confirmatory diagnostic testing and clinical evaluation. Availability and intended use may vary by country/region.